KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Expected to Post Q1 2025 Earnings of ($0.57) Per Share

KalVista Pharmaceuticals, Inc. (NASDAQ:KALVFree Report) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of KalVista Pharmaceuticals in a research note issued to investors on Tuesday, March 12th. HC Wainwright analyst A. Fein forecasts that the specialty pharmaceutical company will post earnings per share of ($0.57) for the quarter. HC Wainwright currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($3.09) per share. HC Wainwright also issued estimates for KalVista Pharmaceuticals’ Q2 2025 earnings at ($0.54) EPS, Q3 2025 earnings at ($0.53) EPS and Q4 2025 earnings at ($0.50) EPS.

Separately, Needham & Company LLC increased their price objective on shares of KalVista Pharmaceuticals from $22.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, February 13th.

Get Our Latest Stock Analysis on KalVista Pharmaceuticals

KalVista Pharmaceuticals Trading Down 4.7 %

Shares of KALV opened at $12.49 on Wednesday. KalVista Pharmaceuticals has a 12-month low of $6.26 and a 12-month high of $16.88. The business’s 50 day moving average is $13.74 and its 200 day moving average is $10.98. The company has a market capitalization of $431.65 million, a PE ratio of -4.08 and a beta of 0.90.

Insiders Place Their Bets

In other KalVista Pharmaceuticals news, CFO Benjamin L. Palleiko sold 22,802 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $14.11, for a total value of $321,736.22. Following the completion of the transaction, the chief financial officer now directly owns 187,315 shares of the company’s stock, valued at $2,643,014.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, major shareholder Venrock Healthcare Capital Par purchased 4,474 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were bought at an average price of $14.74 per share, for a total transaction of $65,946.76. Following the acquisition, the insider now directly owns 4,743,157 shares in the company, valued at $69,914,134.18. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Benjamin L. Palleiko sold 22,802 shares of the business’s stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $14.11, for a total transaction of $321,736.22. Following the sale, the chief financial officer now owns 187,315 shares of the company’s stock, valued at approximately $2,643,014.65. The disclosure for this sale can be found here. In the last 90 days, insiders bought 448,522 shares of company stock valued at $5,806,280 and sold 145,878 shares valued at $1,951,071. 12.30% of the stock is currently owned by insiders.

Institutional Trading of KalVista Pharmaceuticals

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its holdings in KalVista Pharmaceuticals by 24.9% in the first quarter. JPMorgan Chase & Co. now owns 13,424 shares of the specialty pharmaceutical company’s stock valued at $198,000 after buying an additional 2,677 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of KalVista Pharmaceuticals by 5.8% in the first quarter. Bank of New York Mellon Corp now owns 69,570 shares of the specialty pharmaceutical company’s stock valued at $1,026,000 after buying an additional 3,838 shares in the last quarter. MetLife Investment Management LLC grew its position in KalVista Pharmaceuticals by 103.8% in the first quarter. MetLife Investment Management LLC now owns 12,495 shares of the specialty pharmaceutical company’s stock valued at $184,000 after acquiring an additional 6,365 shares in the last quarter. Rhumbline Advisers increased its stake in KalVista Pharmaceuticals by 16.3% during the 1st quarter. Rhumbline Advisers now owns 22,150 shares of the specialty pharmaceutical company’s stock worth $326,000 after buying an additional 3,100 shares during the period. Finally, BlackRock Inc. raised its holdings in KalVista Pharmaceuticals by 2.6% in the first quarter. BlackRock Inc. now owns 1,544,027 shares of the specialty pharmaceutical company’s stock valued at $22,757,000 after acquiring an additional 39,407 shares in the last quarter.

About KalVista Pharmaceuticals

(Get Free Report)

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Featured Stories

Earnings History and Estimates for KalVista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for KalVista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KalVista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.